ONT-093

ONT-093 (OC 144-093) is a potent and orally active inhibitor of P-glycoprotein pump. ONT-093 inhibits P-gp-mediated ATPase activity with an IC50 of 0.16 μM. ONT-093 can inhibit drug efflux and increase bioavailability. ONT-093 reverses cancer cells multidrug resistance to chemotherapeutic drugs. ONT-093 can be used for the researches of cancer and infection, such as colon cancer and malarial [1][2][3].

Product Specifications

CAS Number

[216227-54-2]

Product Name Alternative

OC 144-093; OC 144093

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

P-glycoprotein

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Cancer-programmed cell death

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/ont-093.html

Purity

99.21

Solubility

DMSO : 100 mg/mL (ultrasonic) |Methanol : 125 mg/mL (ultrasonic)

Smiles

CC(C)NC1=CC=C(C2=C(C3=CC=C(NC(C)C)C=C3)N=C(C4=CC=C(/C=C/COCC)C=C4)N2)C=C1

Molecular Formula

C32H38N4O

Molecular Weight

494.67

Precautions

H302, H315, H319, H335

References & Citations

[1]Newman MJ, et al. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res. 2000 Jun 1;60 (11) :2964-72.|[2]Chi KN, et al. A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. Invest New Drugs. 2005 Aug;23 (4) :311-5.|[3]Sanchez CP, et al. Polymorphisms within PfMDR1 alter the substrate specificity for anti-malarial drugs in Plasmodium falciparum. Mol Microbiol. 2008 Nov;70 (4) :786-98.